Materiały źródłowe

• #1 Epidemiology of bronchiectasis – PubMed

  https://pubmed.ncbi.nlm.nih.gov/39384303/

  Bronchiectasis is a chronic respiratory disease characterised by permanent enlargement of the airways associated with cough, sputum production and a history of pulmonary exacerbations. In the past few years, incidence and prevalence of bronchiectasis have increased worldwide, possibly due to advances in imaging techniques and disease awareness, leading to increased socioeconomic burden and healthcare costs. Consistently, a mortality increase in bronchiectasis patient cohorts has been demonstrated in certain areas of the globe, with mortality rates of 16-24.8% over 4-5 years of follow-up. However, heterogeneity in epidemiological data is consistent, as reported prevalence in the general population ranges from 52.3 to more than 1000 per 100 000. […] Methodological flaws in the designs of available studies are likely to underestimate the proportion of people suffering from this condition worldwide and comparisons between different areas of the globe might be unreliable due to different assessment methods or local implementation of the same method in different contexts.

• #2 Bronchiectasis – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK430810/

  Bronchiectasis predominance is not clearly understood. Global statistics suggest that the incidence of bronchiectasis has risen over the past few years. It can exist in any age group. However, it generally occurred in childhood during the pre-antibiotic period. Recent evidence shows that bronchiectasis disproportionately affects women and older individuals, and may be contributing to an increasing healthcare burden.

• #3 Prevalence of bronchiectasis in adults: a meta-analysis | BMC Public Health | Full Text

  https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-024-19956-y

  Bronchiectasis, once considered an orphan disease, is receiving attention globally owing to its increasing prevalence, healthcare burden, and associated morbidity. […] The pooled prevalence of bronchiectasis in adults from 15 studies covering 437,851,478 individuals was 680 per 100,000 (95% CI: 634727 per 100,000). […] Subgroup analysis showed that the prevalence of bronchiectasis in the United States, Korea, and China was 478 per 100,000 (95% CI: 367588 per 100,000), 886 per 100,000 (95% CI: 778993 per 100,000), and 759 per 100,000 (95% CI: 352399 per 100,000), respectively; 467 per 100,000 (95% CI: 416518 per 100,000) in males and 535 per 100,000 (95% CI: 477592 per 100,000) in females; […] The estimated prevalence according to our study is higher than that reported for some European countries.

• #4 Prevalence of bronchiectasis in adults: a meta-analysis | BMC Public Health | Full Text

  https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-024-19956-y

  The estimated prevalence in the United States, Korea, and China was 478 per 100,000 persons, 886 per 100,000 persons, and 759 per 100,000 persons, respectively. […] The high prevalence of bronchiectasis observed in this study confirms that it should no longer be considered an orphan disease, but rather a common chronic respiratory disease.

• #5 Global Epidemiology and Impact of Bronchiectasis in Adults without Cystic Fibrosis | SpringerLink

  https://link.springer.com/chapter/10.1007/978-3-031-12926-1_2

  The incidence and prevalence of bronchiectasis have increased over recent years, and it is no longer considered a rare or orphan disease. […] Most data on bronchiectasis incidence and prevalence comes from higher income countries across Asia, Europe, and North America, but there are ongoing efforts to systematically identify and evaluate bronchiectasis in other regions. […] Bronchiectasis incidence and prevalence increase with age and is generally more common in females. […] Hospitalization rates are low but associated with a significant cost. […] Mortality rates are higher in those with bronchiectasis than in age-matched populations, but most patients with bronchiectasis die of other causes.

• #6 Bronchiectasis: Practice Essentials, Background, Pathophysiology

  https://emedicine.medscape.com/article/296961-overview

  A more recent study showed that the number of adults receiving treatment for bronchiectasis in the US is estimated to be 340,000 to 522,000. Of this population, most are women (67%) and most are aged 65 years (76%). […] The prevalence of bronchiectasis significantly increases with age, from 7 per 100,000 persons aged 18-34 years to 812 per 100,000 persons aged 75 years, and it is more common in women. […] Bronchiectasis may be underdiagnosed in general because it is no longer included in survey data and often goes unreported. The exception is bronchiectasis associated with CF; the latter occurs with a prevalence of 1 in 2500 white births. CF is the largest single cause of chronic lung infections and bronchiectasis in industrialized nations. […] Native Americans in Alaska comprise a subgroup with higher-than-expected prevalence, with a 4-fold higher rate of bronchiectasis than the general population. […] Overall, identifying the true frequency remains a challenge, given the lack of specific symptoms and lack of readily available noninvasive screening tests for population studies.

• #7 Clinical manifestations and diagnosis of bronchiectasis in adults – UpToDate

  https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-bronchiectasis-in-adults

  Bronchiectasis shares many clinical features with chronic obstructive pulmonary disease (COPD), including inflamed and easily collapsible airways, obstruction to airflow, and frequent office visits and hospitalizations. The epidemiology, major clinical manifestations, and diagnostic approach to bronchiectasis will be reviewed here. […] The prevalence of bronchiectasis is provided by independent analyses of International Classification of Diseases (ICD) codes from two large and different United States databases. An estimated 350,000 to 500,000 adults have bronchiectasis in the United States. The prevalence of bronchiectasis increases with age with an 8- to 10-fold difference in prevalence after the age of 60 years (300 to 500 per 100,000) as compared to ages <40 to 50 years (40 to 50 per 100,000). Reports from the United Kingdom and Germany describe similar marked age differences in prevalence. The Medicare (age ≥65 years) survey of pulmonary specialty-recorded diagnoses had an annual prevalence of 701 per 100,000 persons.

• #8 British Thoracic Society Guideline for bronchiectasis in adults | Thorax

  https://thorax.bmj.com/content/74/Suppl_1/1

  UK data in 2013 revealed the prevalence in women was 566/100 000 and in men 486/100 000. […] Data from 12 US states over the period 1993-2006 demonstrate an average annual age-adjusted hospitalisation rate of 16.5 hospitalisations per 100 000 population. Women and those aged over 60 years had the highest rate of hospitalisations. […] New Zealand hospital admission rates are reported as 25.7 per 100 000, highest in childhood and the elderly, and related to sex, socioeconomic deprivation and race. […] Regarding co-morbidity coding that may provide information on aetiology, the UK data found no significant co-morbidity in 34% of patients, and the most common coded co-morbidities to be asthma (42%) and COPD (36%). […] A previous diagnosis of idiopathic bronchiectasis should prompt careful reinvestigation for a primary cause in the context of a deteriorating clinical course or a young patient.

• #8 British Thoracic Society Guideline for bronchiectasis in adults | Thorax

  https://thorax.bmj.com/content/74/Suppl_1/1

  Referral to a specialist centre for investigation should be considered for young patients and those with apparent idiopathic bronchiectasis especially where there is evidence of progressive disease. […] All patients with bronchiectasis should undergo routine monitoring in order to identify disease progression, pathogen emergence and modify treatment where necessary. […] Consider patients with chronic P. aeruginosa colonisation at higher risk of bronchiectasis-related complications. […] Perform regular sputum microbiology screening for patients with clinically significant bronchiectasis to monitor for pathogens and detect new isolation of P. aeruginosa.

• #9 Bronchiectasis Market Insight, Epidemiology and Market

  https://www.globenewswire.com/news-release/2024/12/09/2993632/28124/en/Bronchiectasis-Market-Insight-Epidemiology-and-Market-Forecast-to-2034.html

  In 2023, among the 7MM, Japan had approximately 96,580 diagnosed prevalent cases of NCFB. […] In 2023, among the 7MM, the US accounted for the highest number of diagnosed prevalent cases of cystic fibrosis bronchiectasis, with approximately 41,566 cases, while Japan accounted for the least, with only 59 cases. […] The bronchiectasis market is set for steady growth, with a robust compound annual growth rate (CAGR) anticipated from 2024 to 2034. This expansion in the 7MM is driven by the introduction of innovative therapies such as Brensocatib, and CMS I-neb, as well as advances in diagnostic techniques and the rising prevalence of bronchiectasis. […] A critical unmet need in bronchiectasis is the lack of approved, disease-specific therapies. Current treatments primarily focus on symptom management rather than addressing the underlying pathology, creating a significant gap in effective long-term solutions and driving demand for targeted, innovative drug development.

• #9 Bronchiectasis Market Insight, Epidemiology and Market

  https://www.globenewswire.com/news-release/2024/12/09/2993632/28124/en/Bronchiectasis-Market-Insight-Epidemiology-and-Market-Forecast-to-2034.html

  In 2023, there were approximately 1,028,651 diagnosed prevalent cases of NCFB in the 7MM. Of these, the US accounted for approximately 37% of the cases, EU4 and the UK countries accounted for around 54%, followed by Japan which represented nearly 9%. […] In 2023, there were approximately 77,445 diagnosed prevalent cases of cystic fibrosis bronchiectasis across the 7MM. Of these, the US accounted for about 53.7%, EU4 and the UK made up around 46.3%, and Japan represented nearly 0.1% of cases. […] In the 7MM, the total diagnosed prevalent cases of NCFB were approximately 1,028,651 in 2023. This number is anticipated to rise during the forecast period (2024-2034), driven by increased awareness and screening, along with advancements in diagnostic techniques. […] In 2023, the US accounted for the highest number of diagnosed prevalent cases of NCFB, with approximately 380,711 cases, while France accounted for the least, with only 37,576 cases.

• #10 Geographic variation in the aetiology, epidemiology and microbiology of bronchiectasis | BMC Pulmonary Medicine | Full Text

  https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-018-0638-0

  Incidence and prevalence rates of bronchiectasis in the UK have increased annually from 2004 and are associated with significant mortality. […] Seitz et al. (2012) reported an annual increase of 8.7% in the prevalence of bronchiectasis in the US with a higher prevalence in Asian Americans when compared to European and African Americans. […] In the Asian subcontinent, considerable gaps in our understanding of bronchiectasis epidemiology continue to exist. No comprehensive prevalence datasets for either China or India are currently available however work is currently ongoing to address this.

• #10 Geographic variation in the aetiology, epidemiology and microbiology of bronchiectasis | BMC Pulmonary Medicine | Full Text

  https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-018-0638-0

  Bronchiectasis is a disease associated with chronic progressive and irreversible dilatation of the bronchi and is characterised by chronic infection and associated inflammation. The prevalence of bronchiectasis is age-related and there is some geographical variation in incidence, prevalence and clinical features. […] The global shift in ageing will continue to influence the burden of bronchiectasis, its disease epidemiology and implications for the healthcare systems that provide therapy. […] The most striking variation in bronchiectasis epidemiology is observed among indigenous children of Australia, Alaska, Canada and New Zealand. Here, paediatric populations exhibit exceptionally high rates compared to non-indigenous groups with infant or childhood pneumonia cited as the primary cause in many cases.

• #11 Learn About Bronchiectasis | American Lung Association

  https://www.lung.org/lung-health-diseases/lung-disease-lookup/bronchiectasis/learn-about-bronchiectasis

  Bronchiectasis affects 350,000 to 500,000 adults in the United States. The risk of developing bronchiectasis increases with age. […] Bronchiectasis is more common in women than in men. […] Women are at higher risk, although men also can have bronchiectasis.

• #12

  https://link.springer.com/article/10.1007/s13665-023-00317-w

  The burden of bronchiectasis has been increasing globally over the last decade. […] Data from national registries suggest geographical variations in aetiology and prevalence, which has further led to the creation of national guidelines for the management of bronchiectasis. […] As there is a significant geographical variation in the aetiology, epidemiology, microbiology and severity of bronchiectasis, the appropriate prognostication score needs to be chosen and validated in the local population. […] The geographical variation in the aetiology, pattern and distribution of bronchiectasis alludes to the need for developing clinical guidelines for the local population.

• #13 Prevalence – Bronchiectasis

  https://bronchiectasis.com.au/bronchiectasis/bronchiectasis/prevalence

  Pacific children aged under 15 years have an estimated incidence rate of bronchiectasis of 17.8 per 100,000. […] In 2003, the incidence of bronchiectasis in Auckland children was 24/100,000 for Mori compared to 4/100,000 for European groups. […] Another New Zealand study reported the incidence as 4.8 per 100,000 children compared with 1.5 per 100,000 for the European population. […] The rate of hospitalisations for bronchiectasis in 2003-2005 were 3.6 times the rate for non-Mori, with the rate rising to 6-fold at ages 45-64 years. […] In 2000, 27% of adults in South Auckland hospitalised with bronchiectasis were Mori (Roberts et al, 2012). […] A recent study has shown hospital admission rates to be 5-fold higher for Mori than Non-Mori (Bibby et al, 2015). […] In the United States, a 2005 study estimated a range from 4.2/100,000 in the 18-34 years age group to 272/100,000 in those over 75 years of age.

• #14

  https://bpac.org.nz/bpj/2012/september/bronchiectasis.aspx

  Bronchiectasis disproportionately affects Mori and Pacific peoples and people from lower socioeconomic communities. […] The rate of bronchiectasis in New Zealand adults is not known, however, prevalence increases with age. […] In New Zealand, Pacific children aged under 15 years have an estimated incidence rate of bronchiectasis of 17.8 per 100 000. […] Capital Coast DHB reported that from 2002 – 2006, the risk of being hospitalised due to bronchiectasis was almost 11 times higher for a Pacific child aged under 14 years and four times higher for a Mori child, than for a New Zealand European child. […] Socioeconomic deprivation is associated with an increased risk of developing bronchiectasis. The relative risk of a child living in a decile nine or ten community (most deprived) developing bronchiectasis is over 15 times higher than for a child living in a decile one area (least deprived).

• #15 Bronchiectasis among Indigenous adults in the Top End of the Northern Territory, 2011–2020: a retrospective cohort study | The Medical Journal of Australia

  https://www.mja.com.au/journal/2024/220/4/bronchiectasis-among-indigenous-adults-top-end-northern-territory-2011-2020

  Objectives: To assess the prevalence of bronchiectasis among Aboriginal and Torres Strait Islander (Indigenous) adults in the Top End of the Northern Territory, and mortality among Indigenous adults with bronchiectasis. […] The estimated prevalence of bronchiectasis was 19.4 per 1000 residents (20.6 per 1000 women; 18.0 per 1000 men). […] The prevalence of bronchiectasis among adult Indigenous Australians in the Top End of the Northern Territory and the associated all-cause mortality are alarmingly high. […] The prevalence is highest among people aged 40 years or more, and is generally higher among women than men and in rural and remote areas than in urban communities. […] Characterising the epidemiology of bronchiectasis in Indigenous Australia is crucial for its accurate diagnosis and effective management, as well as for designing population-level strategies for improving health outcomes.

• #16 Bronchiectasis among Indigenous adults in the Top End of the Northern Territory, 2011–2020: a retrospective cohort study | The Medical Journal of Australia

  https://www.mja.com.au/journal/2024/220/4/bronchiectasis-among-indigenous-adults-top-end-northern-territory-2011-2020

  The estimated prevalence of bronchiectasis in the Top End Health Service region in 2011 was 19.4 per 1000 Indigenous adults, four times the estimated prevalence in the United Kingdom at about the same time. […] All-cause mortality was high among people with CT-confirmed bronchiectasis (42% to April 2023). […] All-cause mortality among Indigenous adults with bronchiectasis during the follow-up period was 42% (195 of 459), and the median age at death was low (60.3 years; IQR, 50.3-68.9 years). […] The bronchiectasis disease burden among Indigenous adults in the NT Top End is high, with differences in its prevalence by health district, as is all-cause mortality among adults with bronchiectasis.

• #17 Bronchiectasis | Diagnosis & Disease Information – Pulmonology Advisor

  https://www.pulmonologyadvisor.com/ddi/bronchiectasis/

  No recent large systematic studies or reviews have evaluated the prevalence of bronchiectasis. Based on several older studies of patients outside the United States, the estimated prevalence ranges from 53 to 566 cases per 100,000 people. The American Lung Association estimates that in the United States, bronchiectasis affects 350,000 to 500,000 adults. The condition may be more common in women than in men, and the prevalence increases with age. […] Advanced age (older than 60 years), smoking, female sex, and low body mass index are associated with an increased risk for bronchiectasis. […] The most current guidelines for bronchiectasis are the European Respiratory Society guidelines for the management of adult bronchiectasis, which were last updated in 2017.

• #18 Bronchiectasis – Pulmonary Disorders – MSD Manual Professional Edition

  https://www.msdmanuals.com/professional/pulmonary-disorders/bronchiectasis-and-atelectasis/bronchiectasis

  Bronchiectasis is estimated to affect 680/100,000 individuals annually worldwide (1). […] Bronchiectasis may be diffuse (affecting many areas of the lungs) or focal (appearing in only 1 or 2 lung areas). […] The cause of many cases appears initially to be idiopathic, probably partly because onset is so slow that the triggering problem is not readily evident at the time bronchiectasis is recognized. […] However, after thorough investigation using genetic and immunologic testing, an etiology is more often found in these idiopathic cases (2). […] Bronchiectasis also often coexists with more common conditions like chronic obstructive pulmonary disease (COPD) and asthma. […] It is an increasingly recognized complication of chronic, recurrent aspiration and gastroesophageal reflux. […] In regions where tuberculosis is common, bronchiectasis is a common complication, particularly in patients with impaired immune function due to undernutrition or human immunodeficiency virus (HIV) infection.

• #18 Bronchiectasis – Pulmonary Disorders – MSD Manual Professional Edition

  https://www.msdmanuals.com/professional/pulmonary-disorders/bronchiectasis-and-atelectasis/bronchiectasis

  Bronchiectasis represents a common end-point of several disorders predisposing to chronic airway inflammation. […] The most widely accepted model describes a „vicious cycle” that results in airway damage and dilation (1). […] This process perpetuates, ultimately resulting in irreversible airway damage if the cycle continues untreated (2). […] Colonization with P. aeruginosa tends to indicate severe disease and predicts worse outcomes, including increased risk of exacerbations, hospitalization, poor quality of life, rapid decline in lung function, and death. […] Colonization by multiple organisms is common, and antibiotic resistance is a concern in patients who require frequent courses of antibiotics for treatment of exacerbations. […] Diagnosis is based on history, physical examination, and radiologic testing, beginning with a chest radiograph.

• #19 Recommendations for aetiological diagnosis of bronchiectasis | Pulmonology

  https://www.journalpulmonology.org/en-recommendations-for-aetiological-diagnosis-bronchiectasis-articulo-S2173511516300033

  In a cohort study 98% of adults and 61% of children with primary ciliary dyskinesia had BE. […] The prevalence of BE in ABPA ranges from 69 to 78% in different studies. […] The true prevalence of BE among children with CF is unknown; however, studies have shown that 50-70% of patients have HRCT-defined bronchiectasis by 35 years of age. […] BE has been reported in up to 76% of patients with CVID, being more frequent in cohorts with a longer diagnosis delay. […] The prevalence of BE in patients with COPD is highly variable (27-74%), probably in relation with the criteria used to define BE. […] The prevalence of BE in asthma is described between 17.5 and 28%. […] The prevalence of BE in PBD is 100% in advanced stages. […] In a study by Pasteur et al. considering several BE aetiological factors, GERD was identified as causative factor in 4% of patients.

• #20 Bronchiectasis: Practice Essentials, Background, Pathophysiology

  https://emedicine.medscape.com/article/1004692-overview

  Evidence suggests that non-CF-related bronchiectasis is more common and more virulent in women, particularly slender white women older than 60 years. In these patients, bronchiectasis is often caused by primary Mycobacterium avium complex (MAC) infection and has been called the Lady Windermere syndrome, named after a character in a novel by Oscar Wilde. […] An epidemiologic study of bronchiectasis-associated hospitalizations in the United States demonstrated that the hospitalization rate for this disorder increased from 1993-2006, especially in persons older than 60 years. No specific single underlying diagnosis has been associated with this apparent increase in the burden of disease in the elderly. […] Although limited, epidemiologic studies suggest that persons aged 60-80 years have the highest frequency of bronchiectasis again likely from the rise in atypical mycobacterial infections. The differences in prevalence between age groups are a direct reflection of the differences in prevalence of the underlying causes of bronchiectasis, lung disease, and/or chronic infections.

• #21 Bronchiectasis | Open Respiratory Archives

  https://www.elsevier.es/en-revista-open-respiratory-archives-11-avance-resumen-bronchiectasis-S2659663624000420

  Non-cystic fibrosis bronchiectasis, a condition that remains relatively underrecognized, has garnered increasing research focus in recent years. This scientific interest has catalyzed advancements in diagnostic methodologies, enabling comprehensive clinical and molecular profiling. Such progress facilitates the development of personalized treatment strategies, marking a significant step toward precision medicine for these patients. […] Bronchiectasis poses significant diagnostic challenges in both clinical settings and research studies. While computed tomography (CT) remains the gold standard for diagnosis, novel alternatives are emerging. These include artificial intelligence-powered algorithms, ultra-low dose chest CT, and magnetic resonance imaging (MRI) techniques, all of which are becoming recognized as feasible diagnostic tools.

• #21 Bronchiectasis | Open Respiratory Archives

  https://www.elsevier.es/en-revista-open-respiratory-archives-11-avance-resumen-bronchiectasis-S2659663624000420

  The precision medicine paradigm calls for refined characterization of bronchiectasis patients by analyzing their inflammatory and molecular profiles. Research into the underlying mechanisms of inflammation and the evaluation of biomarkers such as neutrophil elastase, mucins, and antimicrobial peptides have led to the identification of distinct patient endotypes. These endotypes present variable clinical outcomes, necessitating tailored therapeutic interventions. […] Recent observations have shown that categorizing bronchiectasis patients based on a heterogeneous group of endotypes could be more effective, allowing for the development of more specific therapies to effectively treat our patients. […] The variety of diseases associated with bronchiectasis, along with the absence of standardized definitions, has presented challenges both in clinical practice and in clinical trials for treatments targeting this condition. Accordingly, criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults have recently been proposed. […] In summary, efforts are currently focused on developing new and promising treatments that have the potential to significantly enhance the management of non-cystic fibrosis bronchiectasis patients.

• #22 Genomic epidemiology and characterization of difficult-to-treat resistant Pseudomonas aeruginosa isolates co-harboring blaOXA-50 and crpP causing bronchiectasis | Scientific Reports

  https://www.nature.com/articles/s41598-025-95950-7

  Difficult-to-treat resistant Pseudomonas aeruginosa (DTR-PA) is an MDR subset resistant to all first-line antipseudomonal agents. It is particularly concerning in respiratory infections like bronchiectasis, leading to poor outcomes, limited treatment options, and higher healthcare costs. In 2021, 38 multidrug-resistant P. aeruginosa isolates were collected from bronchiectasis patients from a single medical center in Ningbo, China. […] The emergence of DTR-PA in bronchiectasis and other chronic respiratory conditions represents a significant clinical challenge. Patients with bronchiectasis frequently experience recurrent infections, and colonization with DTR-PA is associated with poorer clinical outcomes, including increased exacerbations, reduced lung function, and higher mortality rates.

• #23 Bronchiectasis | Open Respiratory Archives

  https://www.elsevier.es/en-revista-open-respiratory-archives-11-articulo-bronchiectasis-S2659663624000420

  Biomarkers are needed to categorize and measure the biological activity of this disease. […] Recent findings from national registries, such as RIBRON, and international databases like EMBARC, which focus on bronchiectasis, have revealed that up to 20% of bronchiectasis patients present peripheral eosinophilia with a blood eosinophil count of at least 300 eosinophils/mL or fractional exhaled nitric oxide (FENO) 25 ppb. […] Eosinophilic bronchiectasis appears to represent a distinct and prevalent subtype of individuals, presenting unique prognostic factors and treatment considerations. Consequently, its recognition is imperative when managing patients with bronchiectasis.

• #23 Bronchiectasis | Open Respiratory Archives

  https://www.elsevier.es/en-revista-open-respiratory-archives-11-articulo-bronchiectasis-S2659663624000420

  Recent observations have shown that categorizing bronchiectasis patients based on a heterogeneous group of endotypes could be more effective, allowing for the development of more specific therapies to effectively treat our patients. […] The variety of diseases associated with bronchiectasis, along with the absence of standardized definitions, has presented challenges both in clinical practice and in clinical trials for treatments targeting this condition. […] An internationally harmonized, adapted and standardized diagnostic algorithm is needed to prevent PCD underdiagnosis. […] Neutrophilic inflammation plays a key role in the pathophysiology and progression of bronchiectasis. […] The dysregulated inflammatory response results in lung damage, abnormal and irreversible dilatation of the bronchi, and recurrent respiratory infections.

• #24 Bronchiectasis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  https://www.researchandmarkets.com/reports/5970009/bronchiectasis-market-epidemiology-industry?srsltid=AfmBOoqTQsliJHBYb7FIzgSoy6WqmISnvBFLX9wwj3LF8ZZi17sOAGoD

  The 7 major bronchiectasis markets reached a value of US$ 438.5 Million in 2023. Looking forward, the publisher expects the 7MM to reach US$ 731.5 Million by 2034, exhibiting a growth rate (CAGR) of 5.85% during 2023-2034. […] This report provides an exhaustive analysis of the bronchiectasis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. […] According to the report the United States has the largest patient pool for bronchiectasis and also represents the largest market for its treatment. […] This report also provides a detailed analysis of the current bronchiectasis marketed drugs and late-stage pipeline drugs.

• #25 Bronchiectasis – Market Insight, Epidemiology and Market Forecast – 2034

  https://www.researchandmarkets.com/reports/5524217/bronchiectasis-market-insight-epidemiology?srsltid=AfmBOoqI5ph9iX0i4c_HiveRZF2nuMlu_mPMriPSfztdxWy9wuBXDwnI

  According to the analyst’s estimates, in 2023, there were approximately 1,028,651 diagnosed prevalent cases of NCFB in the 7MM. Of these, the US accounted for approximately 37% of the cases, EU4 and the UK countries accounted for around 54%, followed by Japan which represented nearly 9%. […] The analyst’s estimates indicate that in 2023, there were approximately 77,445 diagnosed prevalent cases of cystic fibrosis bronchiectasis across the 7MM. Of these, the US accounted for about 53.7%, EU4 and the UK made up around 46.3%, and Japan represented nearly 0.1% of cases. […] According to the analyst’s epidemiology model, in the 7MM, the total diagnosed prevalent cases of NCFB were approximately 1,028,651 in 2023. This number is anticipated to rise during the forecast period (2024-2034), driven by increased awareness and screening, along with advancements in diagnostic techniques.

• #26 Bronchiectasis – Market Insight, Epidemiology and Market Forecast – 2034

  https://www.researchandmarkets.com/reports/5524217/bronchiectasis-market-insight-epidemiology?srsltid=AfmBOoqI5ph9iX0i4c_HiveRZF2nuMlu_mPMriPSfztdxWy9wuBXDwnI

  In 2023, the US accounted for the highest number of diagnosed prevalent cases of NCFB, with approximately 380,711 cases, while France accounted for the least, with only 37,576 cases. […] Among EU4 and the UK, the UK accounted for the highest number of diagnosed prevalent cases of NCFB, with approximately 224,976 cases in 2023, followed by Spain with approximately 149,236 cases, and Italy with nearly 89,584 cases. […] In 2023, among the 7MM, the US accounted for the highest number of diagnosed prevalent cases of cystic fibrosis bronchiectasis, with approximately 41,566 cases, while Japan accounted for the least, with only 59 cases. […] In 2023, the majority of etiology-specific diagnosed prevalent cases of cystic fibrosis bronchiectasis in Japan were attributed to Staphylococcus aureus, accounting for 36 cases.

• #27 Non-Cystic Fibrosis Bronchiectasis Market Insight,

  https://www.globenewswire.com/news-release/2024/12/03/2990331/28124/en/Non-Cystic-Fibrosis-Bronchiectasis-Market-Insight-Epidemiology-and-Market-Forecast-2024-2034.html

  According to the analyst’s estimates, in 2023, there were approximately 1,028,651 diagnosed prevalent cases of Non-Cystic Fibrosis Bronchiectasis (NCFB) in the 7MM. Of these, the US accounted for approximately 37% of the cases, EU4 and the UK countries accounted for around 54%, followed by Japan which represented nearly 9%. […] According to the analyst’s epidemiology model, in the 7MM, the total diagnosed prevalent cases of NCFB were approximately 1,028,651 in 2023. This number is anticipated to rise during the forecast period (2024-2034), driven by increased awareness and screening, along with advancements in diagnostic techniques. […] In 2023, the US accounted for the highest number of diagnosed prevalent cases of NCFB, with approximately 380,711 cases, while France accounted for the least, with only 37,576 cases.

• #28 Non-Cystic Fibrosis Bronchiectasis Market Insight,

  https://www.globenewswire.com/news-release/2024/12/03/2990331/28124/en/Non-Cystic-Fibrosis-Bronchiectasis-Market-Insight-Epidemiology-and-Market-Forecast-2024-2034.html

  Among EU4 and the UK, the UK accounted for the highest number of diagnosed prevalent cases of NCFB, with approximately 224,976 cases in 2023, followed by Spain with approximately 149,236 cases, and Italy with nearly 89,584 cases. […] In Japan in 2023, the majority of etiology-specific diagnosed prevalent cases of NCFB were attributed to unknown or idiopathic causes, accounting for 32,837 cases. […] In 2023, Japan had approximately 96,580 diagnosed prevalent cases of NCFB.

• #29 Bronchiectasis – Global Allergy & Airways Patient PlatformExpandExpandExpandExpandExpandExpandToggle MenuScroll to topScroll to topExpandExpandExpandExpandExpandExpand

  https://gaapp.org/diseases/bronchiectasis

  Bronchiectasis was originally called a “rare disease,” but with more research and increased awareness that led to better diagnosis, it is now accepted as the third most common lung disease in the world after asthma and COPD, affecting many adults and children. […] World-view perspectives from allergy/immunology and pulmonology specialists in the diagnosis, epidemiology, therapeutic endpoints, and advancements in treatment for non-CF bronchiectasis (NCFB). […] The healthcare practitioners and patient advocates discuss the world-view perspectives from allergy/immunology and pulmonology specialists in the diagnosis, epidemiology, therapeutic endpoints, and advancements in treatment for non-cf bronchiectasis as well as disease management and lifestyle factors are involved from a patient’s perspective when choosing treatment options and stigmas associated with the diagnosis.

• #30 Pathophysiology of Chronic Bronchial Infection in Bronchiectasis | Archivos de Bronconeumología

  https://www.archbronconeumol.org/en-pathophysiology-chronic-bronchial-infection-in-articulo-S0300289622005257

  Bronchiectasis is a common chronic respiratory disease, clinically characterized by a syndrome of cough, sputum production and respiratory infections, and radiologically by abnormal and permanent dilatation of the bronchi. It is associated with poor clinical outcomes, including worse quality of life and increased mortality. Its incidence and prevalence has increased in the last 10 years, especially in older age groups. […] Understanding the molecular mechanisms leading to development of airway inflammation and bacterial persistence in bronchiectasis are essential to find new treatments and to improve the management for this disease. […] Chronic bronchial infection is a common event in bronchiectasis and it is associated with poor outcomes. Several infectious agents such as bacteria, mycobacteria and fungi have been isolated from these patients.

• #31 Pathophysiology of Chronic Bronchial Infection in Bronchiectasis | Archivos de Bronconeumología

  https://www.archbronconeumol.org/en-pathophysiology-chronic-bronchial-infection-in-articulo-S0300289622005257

  A recent systematic review estimated the overall NTM prevalence in adults without CF bronchiectasis to be 10%. […] Chronic bronchial infection by bacteria, mycobacteria, fungi and/or viruses is common in bronchiectasis and has been related to worse clinical outcomes. The persistence of an infectious agent in the airways of patients with bronchiectasis is the result of multiple defects in the immune response and different microorganisms defence mechanisms, which leads to the development of chronic bronchial infection. Although significant progress has already been made, further studies focusing on epidemiology, risk factors, microbiological agents, and clinical relevance in relation to inflammatory endophenotypes are needed. Understanding the pathophysiology of chronic bronchial infection is essential to personalize future treatments and to improve the management of patients with bronchiectasis.

Zobacz więcej